公开(公告)号：US10329274B2

公开(公告)日：2019-06-25

申请号：US15886192

申请日：2018-02-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qingjie Liu ,  Scott Hunter Watterson ,  John E. Macor ,  Khehyong Ngu ,  Saleem Ahmad

IPC: A01N57/26 ,  A61K31/66 ,  A01N43/00 ,  A61K31/397 ,  C07D401/10 ,  A61P29/00 ,  C07D403/12 ,  C07D209/08 ,  C07D209/18 ,  C07D487/10 ,  C07D487/04 ,  C07D471/04 ,  C07D417/04 ,  C07D413/04 ,  C07D403/10 ,  C07D403/04 ,  C07D401/12 ,  C07D401/06 ,  C07D401/04 ,  A61P37/00

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US20190119245A1

公开(公告)日：2019-04-25

申请号：US15886192

申请日：2018-02-01

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qingjie Liu ,  Scott Hunter Watterson ,  John E. Macor ,  Khehyong Ngu ,  Saleem Ahmad

IPC: C07D401/10 ,  A61P37/00 ,  C07D403/12 ,  C07D209/08 ,  C07D209/18 ,  C07D487/10 ,  C07D487/04 ,  C07D471/04 ,  C07D417/04 ,  C07D413/04 ,  C07D403/10 ,  C07D403/04 ,  C07D401/12 ,  C07D401/06 ,  C07D401/04 ,  A61P29/00

CPC classification number: C07D401/10 ,  A61P29/00 ,  A61P37/00 ,  C07D209/08 ,  C07D209/18 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US20170260160A1

公开(公告)日：2017-09-14

申请号：US15608340

申请日：2017-05-30

Applicant: Bristol-Myers Squibb Company

Inventor： Qingjie Liu ,  Scott Hunter Watterson ,  Douglas G. Batt ,  Saleem Ahmad ,  Myra Beaudoin Bertrand ,  Hua Gong ,  Weiwei Guo ,  John E. Macor ,  Khehyong Ngu ,  Andrew J. Tebben ,  Joseph A. Tino

IPC: C07D401/10 ,  C07D209/18 ,  C07D401/04 ,  C07D487/04 ,  C07D401/12 ,  C07D471/04 ,  C07D487/10 ,  C07D209/08 ,  C07D401/06

CPC classification number: C07D401/10 ,  C07D209/08 ,  C07D209/18 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US20230192645A1

公开(公告)日：2023-06-22

申请号：US18173170

申请日：2023-02-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qingjie Liu ,  Scott Hunter Watterson ,  John E. Macor ,  Khehyong Ngu ,  Saleem Ahmad

IPC: C07D401/10 ,  C07D403/12 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D209/18 ,  A61P29/00 ,  A61P37/00 ,  C07D209/08

CPC classification number: C07D401/10 ,  C07D403/12 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/10 ,  C07D209/18 ,  A61P29/00 ,  A61P37/00 ,  C07D209/08

Abstract: Disclosed are compounds of Formula (I):




or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

公开(公告)号：US20220348562A1

公开(公告)日：2022-11-03

申请号：US17265840

申请日：2019-08-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Khehyong Ngu

IPC: C07D403/14 ,  A61K31/506 ,  C07D471/04 ,  A61K31/497 ,  C07D401/14 ,  A61K31/437 ,  A61K31/4439 ,  C07D417/14 ,  C07D413/14 ,  A61K31/4184 ,  C07D409/14 ,  A61K31/427 ,  A61K31/4192 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/438

Abstract: The present invention provides compounds of Formula (I): or a pharmaceutically acceptable salt thereof, useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders. Variables rings A, B, R1, R3, R8, and other variables are as defined herein.

公开(公告)号：US20200165222A1

公开(公告)日：2020-05-28

申请号：US16774202

申请日：2020-01-28

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Qingjie LIU ,  Scott Hunter Watterson ,  John E. Macor ,  Khehyong Ngu ,  Saleem Ahmad

IPC: C07D401/10 ,  C07D209/08 ,  A61P37/00 ,  A61P29/00 ,  C07D209/18 ,  C07D487/10 ,  C07D487/04 ,  C07D471/04 ,  C07D417/04 ,  C07D413/04 ,  C07D403/10 ,  C07D403/04 ,  C07D401/12 ,  C07D401/06 ,  C07D401/04 ,  C07D403/12

Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.